With a serum creatinine of 1.70 mg/dL, on furosemide 40 mg, losartan 100 mg, hydrochlorothiazide 25 mg, metformin 500 mg twice daily, and HbA1c 8.2%, should I ask to reduce furosemide to 20 mg or PRN and increase metformin to 1000 mg twice daily?

Medication Management in Diabetes with Renal Impairment and Suboptimal Glycemic Control

Direct Recommendation

You should increase metformin to 1000 mg twice daily, continue your current blood pressure medications (losartan-HCTZ), and reduce furosemide to 20 mg daily or as needed—your creatinine of 1.70 mg/dL likely corresponds to an eGFR that permits safe metformin escalation, and your A1c of 8.2% requires more aggressive glucose control. 1, 2

---

Critical First Step: Calculate Your eGFR

• You must calculate your estimated glomerular filtration rate (eGFR) immediately, as all medication decisions hinge on this value, not serum creatinine alone 1, 3
• A creatinine of 1.70 mg/dL translates to widely varying eGFR values depending on your age, sex, and body size—for example, a 70-year-old woman may have eGFR 30 mL/min/1.73 m², while a 50-year-old man may have eGFR 50 mL/min/1.73 m² 1
• Using creatinine alone rather than eGFR is a common pitfall that leads to inappropriate medication discontinuation, especially in elderly or small-statured patients 1

---

Metformin Dose Escalation Algorithm

If Your eGFR ≥ 45 mL/min/1.73 m²:

• Increase metformin to 1000 mg twice daily (2000 mg total daily) immediately 1, 2
• This dose escalation is safe, guideline-recommended, and necessary given your A1c of 8.2% 1, 3
• Monitor eGFR every 3–6 months at this kidney function level 1, 2
• Population studies demonstrate that metformin use at eGFR 45–60 mL/min/1.73 m² is associated with reduced mortality compared to other glucose-lowering therapies 1, 2

If Your eGFR is 30–44 mL/min/1.73 m²:

• Do NOT increase metformin dose—instead, reduce to a maximum of 1000 mg daily total (500 mg twice daily) 1, 3
• At this eGFR range, metformin dose must be halved to prevent drug accumulation 1, 3
• Consider adding a GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide) to achieve your A1c target, as these agents have documented cardiovascular and renal benefits 1, 3
• Monitor eGFR every 3–6 months 1, 3

If Your eGFR < 30 mL/min/1.73 m²:

• Discontinue metformin immediately—this is an absolute contraindication due to high risk of fatal lactic acidosis 1, 3, 2
• Switch to a GLP-1 receptor agonist as first-line alternative therapy 1, 3
• DPP-4 inhibitors with renal dose adjustment (sitagliptin 25 mg daily or linagliptin without adjustment) are second-line options 1, 3

---

Diuretic Management: Furosemide Dose Reduction

Rationale for Reducing Furosemide:

• Furosemide 40 mg daily can be safely reduced to 20 mg daily or as-needed dosing if you are euvolemic (no leg swelling, no shortness of breath) 4
• The FDA label supports starting doses of 20–80 mg for edema, with dose titration based on clinical response 4
• Loop diuretics promote volume depletion, which can precipitate acute kidney injury and impair metformin clearance, particularly when combined with ACE inhibitors or ARBs like your losartan 5

Clinical Decision Points:

• If you have persistent leg edema or shortness of breath, continue furosemide 40 mg daily 4
• If you are euvolemic with no volume overload symptoms, reduce to furosemide 20 mg daily or use as needed for breakthrough edema 4
• Monitor for signs of volume depletion (dizziness, orthostatic hypotension, rising creatinine) after any diuretic reduction 5

---

Blood Pressure Medication: Continue Losartan-HCTZ

Why Continue Current Regimen:

• Do NOT discontinue or reduce losartan 100 mg-HCTZ 25 mg—ACE inhibitors and ARBs should be continued at maximally tolerated doses in diabetic kidney disease 5
• Small elevations in serum creatinine (up to 30% from baseline) with RAS blockers must not be confused with acute kidney injury and are expected with effective RAS blockade 5
• The ACCORD BP trial demonstrated that patients with up to 30% creatinine increase on intensive blood pressure lowering had no increase in mortality or progressive kidney disease 5

Critical Safety Monitoring:

• Monitor serum potassium periodically when taking losartan-HCTZ, as diuretics can cause hypokalemia (associated with cardiovascular risk) or hyperkalemia (with RAS blockade) 5
• If creatinine rises >30% from baseline or hyperkalemia develops (potassium >5.5 mEq/L), reassess the regimen 5
• Do NOT reduce losartan dose due to fear of creatinine elevation—all clinical trials demonstrating efficacy used maximally tolerated doses, not low doses 5

---

Temporary Metformin Discontinuation Scenarios

Hold Metformin Immediately If:

• Acute illness with volume depletion (sepsis, severe diarrhea, vomiting, dehydration) develops 1, 2
• Hospitalization with elevated acute kidney injury risk occurs 1, 2
• Iodinated contrast imaging is planned and you have history of liver disease, alcoholism, or heart failure 1, 3
• After contrast exposure, re-measure eGFR 48 hours later before restarting metformin 1, 3

---

Additional Considerations for A1c 8.2%

If Metformin Escalation Alone Is Insufficient:

• Add an SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) if eGFR ≥20 mL/min/1.73 m² for additional cardiovascular and renal protection, independent of glucose control 5, 3
• Add a GLP-1 receptor agonist (dulaglutide, liraglutide, semaglutide) for documented cardiovascular benefits and A1c reduction of 1–1.5% 5, 1
• These agents are preferred over sulfonylureas or insulin due to lower hypoglycemia risk and cardiovascular benefits 5, 1

Monitor Vitamin B12:

• Check vitamin B12 levels if you have been on metformin for more than 4 years, as approximately 7% develop deficiency 1, 3

---

Common Pitfalls to Avoid

• Do not discontinue metformin based on creatinine alone—always calculate eGFR first 1, 3
• Do not reduce losartan dose due to minor creatinine elevations (<30%)—this is expected and beneficial 5
• Do not continue furosemide 40 mg if euvolemic—excessive diuresis increases acute kidney injury risk 5
• Do not fail to monitor eGFR every 3–6 months when eGFR <60 mL/min/1.73 m² 1, 3